Recombinant ad35 vectors and related gene therapy improvements

MYPI2025003216A0Undetermined Publication Date: 2021-01-02FRED HUTCHINSON CANCER CENT +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003216
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-13
Filing Date
2020-07-02
Publication Date
2021-01-02
Patent Text Reader

Abstract

The present disclosure provides, among other things, helper-dependent adenoviral serotype 35 (Ad35) vectors. In various embodiments, helper-dependent Ad35 vectors can be used to deliver a therapeutic payload to a subject in need thereof. Exemplary payloads can encode replacement proteins, antibodies, CARs, TCRs, small RNAs, and genome editing systems. In certain embodiments, a helper-dependent Ad35 vector is engineered for integration of a payload into a host cell genome. The present disclosure further includes methods of gene therapy that include administration of a helper-dependent Ad35 vector to a subject in need thereof. No suitable figure
Need to check novelty before this filing date? Find Prior Art